AmerisourceBergen Corporation Logo

AmerisourceBergen Launches Expanded Generic Pharmaceuticals Program

January 11, 2010

Solutions for Long Term Care and Retail Pharmacies

VALLEY FORGE, Pa., Jan 11, 2010 (BUSINESS WIRE) -- AmerisourceBergen (NYSE:ABC), under its' PRxO(R) Generics Solution, today announced a new program for long term care pharmacies and an expanded program for retail pharmacies. The new solutions are tailored to better meet customer needs as generic prescription demands continue to increase.

"With the economic challenges pharmacies are facing, they require a partner who provides an impactful, economic and innovative generics offering that will enable the pharmacy to improve its business," said Russ Procopio, vice president, Generic Sales, AmerisourceBergen Drug Corporation. "Our customers look to AmerisourceBergen to deliver a total value-added offering that maximizes the potential profit of generics."

PRxO Generics LTC - solution for long term care pharmacies

- The Long Term Care solution will increase customers' profits by leveraging a formulary of generic pharmaceuticals specific to their needs. Long term care pharmacies typically require more unit dose and IV prescriptions. "With a commitment to the new program, long term care pharmacies can realize a significant savings and be able to dedicate resources to clinical and operational investments," noted Procopio. "Customers in long term care are looking for solutions like PRxO Generics LTC, which meets the needs of their unique patient population."

PRxO Generics - Retail

- For retail customers, the newer features (which will also be offered under the long term care program) include: access to a select number of customer preferred generics on the PRxO SELECT formulary, which is based on the recommendations of participating PRxO Generics members nationwide; the substitution of a secondary item at the same value if a primary generic is out of stock and 60-day price protection on new generic product introductions.
- At the same time, pharmacies will be able to access the new First to Shelf(TM) solution, which provides new product placement and price protection, as well as auto-ship incentives. Pharmacies will be able to improve their profitability during a generics introductory period.

"This new and expanded PRxO Generics offering is another example of AmerisourceBergen's ongoing efforts to provide our customers with the value solutions they need to maximize their business and serve their patients," said Procopio.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services companies with operations primarily in the United States, Canada. Servicing both healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With more than $71 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people. AmerisourceBergen is ranked #26 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and change in circumstances. Among the factors that could cause actual results to differ materially from those projected, anticipated or implied are the following: changes in pharmaceutical market growth rates; the loss of one or more key customer or supplier relationships; changes in customer mix; customer delinquencies, defaults or insolvencies; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other dispute with customers or suppliers; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; qui tam litigation for alleged violations of laws and regulations governing the marketing, sale and purchase of pharmaceutical products; changes in U.S. legislation or regulatory action affecting pharmaceutical product pricing or reimbursement policies, including under Medicaid and Medicare; changes in regulatory or clinical medical guidelines and/or labeling for the pharmaceutical products we distribute, including certain anemia products; price inflation in branded pharmaceuticals and price deflation in generics; significant breakdown or interruption of our information technology systems; our inability to implement an enterprise resource planning (ERP) system to handle business and financial processes within AmerisourceBergen Drug Corporation's operations and our corporate functions without operating problems and/or cost overruns; success of integration, restructuring or systems initiatives; interest rate and foreign currency exchange rate fluctuations; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States, including potential changes in Canadian provincial legislation affecting pharmaceutical product pricing or service fees or regulatory action by provincial authorities in Canada to lower pharmaceutical product pricing or service fees; the impact of divestitures or the acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; our inability to successfully complete any other transaction that we may wish to pursue from time to time; changes in tax legislation or adverse resolution of challenges to our tax positions; increased costs of maintaining, or reductions in our ability to maintain, adequate liquidity and financing sources; volatility and deterioration of the capital and credit markets; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting our business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for this Fiscal Year Ended September 30, 2009 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.